Company intelligence / Profile preview

Soonhwan EnE

Taipei, Taipei City, Taiwankr.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Senhwa Biosciences is a clinical-stage biotech company developing first-in-class small molecule drugs targeting DNA damage response pathways for cancer and infectious diseases. Its lead asset, Silmitasertib (CX‑4945), has reached Phase 2 trials for bile duct cancer and has shown promise in severe COVID‑19 cases. Pidnarulex (CX‑5461) targets G4 structures and TOP2B with synthetic lethality mechanisms for advanced cancers resistant to standard therapies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Development Center for Biotechnology [Taiwan]Peter MacCallum Cancer Centre [Australia]various academic collaborations

Beyond the preview

Go deeper on Soonhwan EnE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soonhwan EnE.

Explore the full profile